The phase 3 PROTEUS trial has achieved a landmark breakthrough in high-risk localized prostate cancer treatment, becoming the first study to demonstrate that perioperative systemic therapy combined with radical prostatectomy significantly improves both short- and long-term outcomes. The addition of apalutamide to androgen deprivation therapy (ADT) before and after surgery met both dual primary endpoints, marking a potential paradigm shift toward a new standard of care for this challenging patient population.

Clinical Takeaway

After years of unsuccessful attempts to establish benefits with perioperative systemic therapy in high-risk localized prostate cancer, PROTEUS delivers definitive evidence that perioperative apalutamide plus ADT improves outcomes. The trial’s success in meeting dual primary endpoints of pathologic complete response/minimal residual disease (pCR/MRD) and metastasis-free survival (MFS) provides both immediate surgical benefits and meaningful long-term clinical advantages.

Drug Profile & Mechanism

Apalutamide is an oral androgen receptor pathway inhibitor currently FDA-approved for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). The drug works by blocking androgen receptor signaling, a critical pathway driving prostate cancer growth and progression.

Target Population

Patients with high-risk localized prostate cancer who are candidates for radical prostatectomy represent the target population. This patient group faces significant challenges, with up to 50% experiencing disease relapse within 5 years of surgery alone, highlighting the urgent need for more effective treatment approaches.

Study Design

  • Design: Phase 3, randomized, placebo-controlled trial
  • Population: 2,109 patients with high-risk localized prostate cancer from 18 countries
  • Treatment regimen: 12 cycles of perioperative therapy (6 neoadjuvant + 6 adjuvant)
  • Arms: Apalutamide + ADT vs. placebo + ADT
  • Stratification factors: Gleason score, nodal status, geographic region
  • Notable features: Largest phase 3 placebo-controlled trial in this setting; integrated PSMA-PET imaging

Primary Endpoints

  • Dual primary endpoints:
    • Pathologic complete response/minimal residual disease (pCR/MRD)
    • Metastasis-free survival (MFS)
  • Design rationale: Assess both immediate surgical response and long-term clinical benefit

Primary Efficacy Outcomes

  • pCR/MRD Achievement:
    • Apalutamide + ADT: 8.9% vs. placebo + ADT: 1.0%
    • Odds ratio: 10.17 (95% CI: 5.27-19.64; P < .0001)
    • Approximately 9-fold increase in likelihood of achieving pCR/MRD
  • Favorable Residual Cancer Burden (≤ ypT2, N0 ≤ 0.25 cm³):
    • Apalutamide + ADT: 30.6% vs. placebo + ADT: 11.7%
  • Metastasis-Free Survival:
    • 20% reduction in risk of metastasis or death (HR 0.80, 95% CI: 0.67-0.96; P = .0169)
    • 5-year MFS rates: 78.2% (apalutamide + ADT) vs. 73.5% (placebo + ADT)
    • Median MFS not reached in either arm

Secondary Efficacy Outcomes

  • Event-Free Survival:
    • 18.7-month improvement in median EFS: 57.1 vs. 38.4 months
    • HR 0.71 (95% CI: 0.63-0.80; P < .0001)
    • Driven primarily by reductions in biochemical failure and locoregional recurrence
  • Distant Metastasis Prevention:
    • 83% vs. 76% metastasis-free at 5 years
    • HR 0.68 (95% CI: 0.55-0.83; P = .0002)
  • No Evidence of Disease:
    • 21.9% vs. 18.3% at 4 years (P = .04)
  • Time to Subsequent Therapy:
    • Median 6.2 years vs. 3.5 years (2.7-year improvement)
    • HR 0.65 (95% CI: 0.57-0.73; P < .0001)

Safety Profile

The safety profile of apalutamide plus ADT was consistent with known patterns, demonstrating manageable tolerability with infrequent dose modifications:

  • Most common adverse event: Skin rash (33.0% vs. 15.3% with placebo)
  • Treatment interruptions, dose reductions, or discontinuations were infrequent
  • No unexpected safety signals identified
  • Overall safety assessment: Manageable and consistent with established apalutamide safety profile

Expert Commentary

Dr. Mary-Ellen Taplin, Lead Investigator from Dana-Farber Cancer Institute, emphasized the practice-changing potential: “These results have the potential to be practice changing and support perioperative apalutamide plus ADT as a new standard of care for patients with high-risk localized prostate cancer who are candidates for radical prostatectomy.”

Dr. Declan Murphy, Discussant from Peter MacCallum Cancer Centre, noted the comprehensive patient benefits: “I believe that the benefits reported in PROTEUS today, not just in the primary endpoints but also in the delayed and reduced requirement for subsequent therapy, will be very attractive to my patients and will be considered worthwhile.”

Key Clinical Implications

✔ First successful perioperative systemic therapy trial in high-risk localized prostate cancer to demonstrate clear clinical benefit

✔ Dual primary endpoint success provides both immediate surgical advantages and long-term survival benefits

✔ Significant delay in need for subsequent therapy offers improved quality of life and treatment-free intervals

✔ Manageable safety profile supports feasibility of 12-month perioperative treatment regimen

✔ Large, diverse, international study population enhances generalizability across clinical practice settings

Bottom Line

The PROTEUS trial represents a watershed moment in high-risk localized prostate cancer treatment, finally delivering the long-sought evidence that perioperative systemic therapy can meaningfully improve outcomes. With its demonstration of both immediate pathologic benefits and sustained long-term advantages, apalutamide plus ADT is positioned to become the new standard of care for appropriate patients undergoing radical prostatectomy. The trial’s success addresses a critical unmet need and provides clinicians with an evidence-based approach to intensify treatment for their highest-risk patients while maintaining acceptable tolerability.

Sources: